NCT03967522 (CABRAMET) is a Phase 2 clinical trial of Cabozantinib in Metastatic Renal Cell Carcinoma, sponsored by Centre Leon Berard.

Who is sponsoring NCT03967522?

NCT03967522 is sponsored by Centre Leon Berard.

What drugs are being tested in NCT03967522?

Interventions in NCT03967522: Cabozantinib.

What condition does NCT03967522 study?

NCT03967522 studies Metastatic Renal Cell Carcinoma.

Is NCT03967522 still recruiting?

NCT03967522 is currently completed. Last updated 8 August 2025.

Last reviewed 2025-08-08 · How we verify

NCT03967522: CABRAMET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed Phase 2 Last updated 8 August 2025

What this trial tests

Phase 2 trial testing Cabozantinib in Metastatic Renal Cell Carcinoma in 26 participants. Completed in 1 November 2024.

Timeline

29 November 2019

Primary endpoint
22 October 2024

1 November 2024

Quick facts

Lead sponsor	Centre Leon Berard
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	29 November 2019
Primary completion	22 October 2024
Estimated completion	1 November 2024
Sites	12 locations across France

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Metastatic Renal Cell Carcinoma — all drugs for Metastatic Renal Cell Carcinoma →

Sponsor

Centre Leon Berard — full company profile →

Who can join

18 and older, any sex, with Metastatic Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, et al · · 2022 · cited 36× · PMID 34784056 · DOI 10.1002/cncr.34016
Renal cancer: signaling pathways and advances in targeted therapies.
Jiang A, Li J, He Z, Liu Y, et al · · 2024 · cited 18× · PMID 39092291 · DOI 10.1002/mco2.676
Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma-Future or the Past?
Michaelis J, Grabbert M, Sigle A, Yilmaz M, et al · · 2022 · cited 17× · PMID 35954446 · DOI 10.3390/cancers14153777
Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview.
Internò V, De Santis P, Stucci LS, Rudà R, et al · · 2021 · cited 16× · PMID 33925585 · DOI 10.3390/cancers13092114
Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
Granet-Vaissiere E, Lefort F, Domblides C, Larroquette M, et al · · 2023 · cited 11× · PMID 36831392 · DOI 10.3390/cancers15041048
An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives.
Iaxx R, Lefort F, Domblides C, Ravaud A, et al · · 2022 · cited 11× · PMID 35677148 · DOI 10.2147/tcrm.s251673
Emergent immunotherapy approaches for brain metastases.
Wang J, Tawbi HA. · · 2021 · cited 7× · PMID 34859232 · DOI 10.1093/noajnl/vdab138

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Metastatic Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting

Other Centre Leon Berard trials

Trials by the same sponsor.

NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
NCT07515274 — Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer · NA · not yet recruiting
NCT07243483 — Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute My · NA · recruiting
NCT07334990 — Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Canc · NA · not yet recruiting
NCT07414719 — Impact of an HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in the AuRA Region. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03967522 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Leon Berard
Last refreshed: 8 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03967522.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing